-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo Nordisk: In the “SOUL” trial presented at the 2025 American College of Cardiology conference, Rybelsus® showed a more significant reduction in cardiovascular events. Compared to placebo, Rybelsus® reduced the incidence of major adverse cardiovascular events by 14% in adult patients with type 2 diabetes and cardiovascular disease and/or chronic kidney disease.

Zhitongcaijing·03/29/2025 18:49:00
Listen to the news
Novo Nordisk: In the “SOUL” trial presented at the 2025 American College of Cardiology conference, Rybelsus® showed a more significant reduction in cardiovascular events. Compared to placebo, Rybelsus® reduced the incidence of major adverse cardiovascular events by 14% in adult patients with type 2 diabetes and cardiovascular disease and/or chronic kidney disease.